These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 12089368)

  • 21. Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension.
    Cadnapaphornchai MA; McFann K; Strain JD; Masoumi A; Schrier RW
    Kidney Int; 2008 Nov; 74(9):1192-6. PubMed ID: 18716604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exercise blood pressure, cardiac structure, and diastolic function in young normotensive patients with polycystic kidney disease: a prehypertensive state.
    Martinez-Vea A; Bardaj A; Gutierrez C; Garca C; Peralta C; Marcas L; Oliver JA
    Am J Kidney Dis; 2004 Aug; 44(2):216-23. PubMed ID: 15264179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lercanidipine valuable effect on urine protein losses: the RED LEVEL study.
    Robles NR; Calvo C; Sobrino J; Espinel E; Esteban R; Mateos L; Macias JF
    Curr Med Res Opin; 2016 Oct; 32(sup2):29-34. PubMed ID: 27779460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of losartan and amlodipine regarding long-term blood pressure, cardiac and renal protection.
    Peng F; Lin J; Lin L; Tang H
    Int J Mol Med; 2012 Dec; 30(6):1376-86. PubMed ID: 23064712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antihypertensive treatments in adult autosomal dominant polycystic kidney disease: network meta-analysis of the randomized controlled trials.
    Xue C; Zhou C; Dai B; Yu S; Xu C; Mao Z; Ye C; Chen D; Zhao X; Wu J; Chen W; Mei C
    Oncotarget; 2015 Dec; 6(40):42515-29. PubMed ID: 26636542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of amlodipine versus bisoprolol in hypertensive patients on maintenance hemodialysis: A randomized controlled trial.
    Youssef AM; Elghoneimy HA; Helmy MW; Abdelazeem AM; El-Khodary NM
    Medicine (Baltimore); 2021 Dec; 100(51):e28322. PubMed ID: 34941131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients.
    Yilmaz R; Altun B; Kahraman S; Ozer N; Akinci D; Turgan C
    Ren Fail; 2010; 32(8):903-12. PubMed ID: 20722555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Central blood pressure and measures of early vascular disease in children with ADPKD.
    Marlais M; Rajalingam S; Gu H; Savis A; Sinha MD; Winyard PJ
    Pediatr Nephrol; 2019 Oct; 34(10):1791-1797. PubMed ID: 31243534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients.
    Matsuno Y; Minatoguchi S; Fujiwara H;
    Blood Press Suppl; 2011 Apr; 1():12-9. PubMed ID: 21247247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperaldosteronism and cardiovascular risk in patients with autosomal dominant polycystic kidney disease.
    Lai S; Petramala L; Mastroluca D; Petraglia E; Di Gaeta A; Indino E; Panebianco V; Ciccariello M; Shahabadi HH; Galani A; Letizia C; D'Angelo AR
    Medicine (Baltimore); 2016 Jul; 95(29):e4175. PubMed ID: 27442639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin resistance is related to left ventricular hypertrophy in patients with polycystic kidney disease type 1.
    Lumiaho A; Pihlajamäki J; Hartikainen J; Ikäheimo R; Miettinen R; Niemitukia L; Lampainen E; Laakso M
    Am J Kidney Dis; 2003 Jun; 41(6):1219-24. PubMed ID: 12776274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Yamada S; Ueda Y; Koide H
    Am J Med Sci; 2012 Jan; 343(1):46-51. PubMed ID: 21760473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epicardial Fat Thickness in Patients with Autosomal Dominant Polycystic Kidney Disease.
    Concistrè A; Petramala L; Scoccia G; Sciomer S; Bisogni V; Saracino V; Iannucci G; Lai S; Mastroluca D; Iacobellis G; Letizia C
    Cardiorenal Med; 2018; 8(3):199-207. PubMed ID: 29723863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled (versus nifedipine) study.
    Sadowski Z; Szwed H; Kuch-Wocial A; Kubasik A; Januszewicz W; Krupa-Wojciechowska B; Polak G; Stejfa M; Dvorak I; Balazovjech I; Dubai G; Simon K
    J Hypertens Suppl; 1998 Aug; 16(3):S55-62. PubMed ID: 9747912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypertension in autosomal dominant polycystic kidney disease: observational study in 207 patients with a mean follow-up of 107 months.
    De Almeida EA; Prata MM
    Rev Port Cardiol; 2007 Nov; 26(11):1173-82. PubMed ID: 18297839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
    Nutahara K; Higashihara E; Horie S; Kamura K; Tsuchiya K; Mochizuki T; Hosoya T; Nakayama T; Yamamoto N; Higaki Y; Shimizu T
    Nephron Clin Pract; 2005; 99(1):c18-23. PubMed ID: 15637459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
    Brosnahan GM; Abebe KZ; Moore CG; Bae KT; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Rahbari-Oskoui FF; Steinman TI; Torres VE; The Halt Pkd Investigators
    Curr Hypertens Rev; 2018; 14(1):39-47. PubMed ID: 29564978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-year follow-up study to evaluate the reduction of left ventricular mass and diastolic function in mild to moderate diastolic hypertensive patients.
    Beltman F; Heesen W; Smit A; May J; de Graeff P; Havinga T; Schuurman F; van der Veur E; Lie K; Meyboom-de Jong B
    J Hypertens Suppl; 1998 Oct; 16(6):S15-9. PubMed ID: 9856379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Echocardiographic evaluation in patients with autosomal dominant polycystic kidney disease and end-stage renal disease.
    Martinez-Vea A; Bardají A; Gutierrez C; Garcia C; Peralta C; Aguilera J; Sanchez P; Vidiella J; Angelet P; Compte T; Richart C; Oliver JA
    Am J Kidney Dis; 1999 Aug; 34(2):264-72. PubMed ID: 10430973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aliskiren improves blood pressure control and prevents cardiac damage in high-risk hypertensive subjects.
    Mazza A; Montemurro D; Zuin M; Schiavon L; Zorzan S; Chondrogiannis S; Ferretti A; Ramazzina E; Rubello D
    Minerva Cardioangiol; 2013 Aug; 61(4):461-9. PubMed ID: 23846012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.